Cowen Starts uniQure BV (QURE) at Outperform

Cowen initiates coverage on uniQure BV (NASDAQ: QURE) with a Outperform rating.

Analyst Ritu Baral commented, "We are initiating on QURE with an Outperform based on its broadly applicable, safe, proprietary baculovirus production AAV5 platform, their promising hemophilia B program (first patient data in 4Q15) and earlier programs. QURE's preclinical BMS-partnered cardiac program could reap value while also providing funding to pursue more targets."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $27.98 yesterday.

You May Also Be Interested In

• Freedom Broker Starts M/I Homes (MHO) at Buy
• AmerX Starts Kodiak AI (KDK) at Hold
• AmerX Starts WidePoint Corp (WYY) at Buy